Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
Announced on March 19, 2026, that it will present new late-breaking Phase 2 data for litifilimab in cutaneous lupus erythematosus (CLE) at the AAD Annual Meeting (March 27-31). The drug recently received FDA Breakthrough Therapy Designation for CLE; Medium impact estimated due to the high clinical significance of breakthrough therapy data.
Korean Translation
2026년 3월 19일, 미국피부과학회(AAD) 연례회의(3월 27-31일)에서 피부 홍반성 루푸스(CLE) 치료제 리티필리맙의 새로운 후기 임상 2상 데이터를 발표할 것이라고 발표함. 해당 약물은 최근 CLE에 대해 FDA로부터 획기적 치료제 지정을 받았으며, 임상 데이터 발표는 통상적으로 5% 이상의 주가 변동을 수반하므로 Medium 중요도로 예상함.
Related Recent Events
Ionis Pharmaceuticals Inc (IONS) · Other
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
6/30/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM